Pharmacological inhibition of YAP/TAZ, either through small molecules such as verteporfin, statins, or dasatinib, or via genetic approaches like CRISPR, represents a promising strategy for addressing Hippo pathway dysregulation in cancer. Here, YAP1 is linked to cancer.